# Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients

> **NCT06888856** · — · NOT_YET_RECRUITING · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06888856
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-19
- **Primary completion:** 2030-03-03
- **Final completion:** 2031-03-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888856, "Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06888856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*